Rsearch Associate University of Tennessee Health Science Center Memphis, Tennessee
BDGR-251 is a novel, directly acting antiviral with outstanding in vivo efficacy in both pre-exposure prophylaxis and post-exposure therapy in murine infection models of Eastern Equine Encephalitis Virus (EEEV). Here, we report on the exposure-response relationship of BDGR-251 in both scenarios. BALB/c mice were intranasally infected with plasmid derived EEEV V105. In the prophylactic studies, drug treatment was started 2 hours prior to infection while in therapeutic studies, treatment was delayed for 48 hours post infection. Rodents were sacrificed to harvest brain and plasma, and drug concentrations and viral load were quantified.
Drug exposure in plasma and brain was found to be dose-proportional. In both prophylactic and therapeutic treatment, the compound showed promising efficacy at a 24 mg/kg dose. Further Insilco PKPD modeling is underway, and the compound seems to be promising for clinical use against EEEV.
Learning Objectives:
Upon completion, participants will be able to understand the basics of PKPD modeling approach and how our drug candidate seems to be promising against the Federal select agent EEEV.
Understand the antiviral potential of BDGR-251
Interpret pharmacokinetics and pharmacodynamics (PK/PD) relationships
